Literature DB >> 9815714

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.

V Rusch1, D Klimstra, E Venkatraman, P W Pisters, J Langenfeld, E Dmitrovsky.   

Abstract

The epidermal growth factor receptor (EGFR) and its ligand transforming growth factor (TGF) alpha are hypothesized to form an autocrine growth loop in non-small cell lung cancer (NSCLC) and to play an important role in tumor formation and progression. We studied the association between overexpression of EGFR, TGF-alpha, or both, and overall survival of patients with resectable NSCLC. Overexpression, defined as >20% of tumor cells staining on immunohistochemistry, was examined in 96 tumor samples from consecutive patients having resection of previously untreated, well-staged NSCLC who were then followed prospectively (median follow-up, 20.7 months). The expression of three other ligands for EGFR (epidermal growth factor, cripto, and amphiregulin) was examined by Northern analysis to determine whether they might also contribute to a potential growth stimulatory loop. Overall, survival was calculated by the method of Kaplan and Meier, and prognostic factors were compared using the log-rank test. Overexpression of EGFR only was found in 32% (31 of 96), of TGF-alpha only in 10% (10 of 96), of both EGFR and TGF-alpha in 38% (37 of 96), and of neither in 19% (19 of 96) of tumors. EGFR and TGF-alpha overexpression was observed in all tumor stages and histological types but was most frequent in squamous cell carcinoma. By univariate and multivariate analyses, only tumor stage, not histology or overexpression of EGFR, TGF-alpha, or both, had a significant impact on overall survival. No expression of epidermal growth factor or cripto was observed at the total cellular RNA level of Northern analysis in tumor or benign lung, suggesting that in NSCLC these ligands may not participate in an autocrine growth stimulatory loop with EGFR. Differential overexpression of amphiregulin in malignant versus normal lung was observed, but this expression pattern did not have a prognostic impact. Thus, EGFR and TGF-alpha overexpression is frequent in early-stage NSCLC but is not associated with a survival difference. These findings suggest that this growth factor/receptor loop is more important for lung tumor formation than for tumor progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815714

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  90 in total

Review 1.  Imaging of lung cancer in the era of molecular medicine.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  Acad Radiol       Date:  2011-01-28       Impact factor: 3.173

Review 2.  Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Authors:  Filip Janku; David J Stewart; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 3.  Targeted therapies for non-small cell lung cancer: an evolving landscape.

Authors:  Sumanta Kumar Pal; Robert A Figlin; Karen Reckamp
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

4.  The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.

Authors:  Yong-Feng Yu; Zhi-Wei Chen; Zi-Ming Li; Zong-Hai Li; Shun Lu
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

5.  Signaling pathways in NSCLC as a predictor of outcome and response to therapy.

Authors:  Anjali K Gupta; Daniel E Soto; Michael D Feldman; Jeffrey D Goldsmith; Rosemarie Mick; Stephen M Hahn; Mitchell Machtay; Ruth J Muschel; W Gillies McKenna
Journal:  Lung       Date:  2004       Impact factor: 2.584

Review 6.  Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.

Authors:  Consuelo Buttigliero; Valentina Bertaglia; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2016-12

7.  Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.

Authors:  Seok Jin Kim; Zahid N Rabbani; Fan Dong; Robin T Vollmer; Ernst-Gilbert Schreiber; Mark W Dewhirst; Zeljko Vujaskovic; Michael J Kelley
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

8.  Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis.

Authors:  W Hilbe; S Dirnhofer; F Oberwasserlechner; W Eisterer; K Ammann; T Schmid; G Hilbe; J Thaler; E Wöll
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

9.  COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.

Authors:  Alison L Van Dyke; Michele L Cote; Geoffrey M Prysak; Gina B Claeys; Angie S Wenzlaff; Valerie C Murphy; Fulvio Lonardo; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

Review 10.  Ligand-Independent EGFR Signaling.

Authors:  Gao Guo; Ke Gong; Bryan Wohlfeld; Kimmo J Hatanpaa; Dawen Zhao; Amyn A Habib
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.